Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
440 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015', provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 11 Therapeutics Development 12 Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview 12 Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis 13 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies 14 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by Universities/Institutes 19 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies 25 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by Universities/Institutes 30 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 32 Altor BioScience Corporation 32 Aprea AB 33 arGEN-X BV 34 Ariad Pharmaceuticals, Inc. 35 Array BioPharma Inc. 36 Astex Pharmaceuticals, Inc. 37 Baxalta Incorporated 38 Bellicum Pharmaceuticals, Inc. 39 Bio-Path Holdings, Inc. 40 Biogenomics Limited 41 BioLineRx, Ltd. 42 BioSight Ltd. 43 Boston Biomedical, Inc. 44 Bristol-Myers Squibb Company 45 Cantargia AB 46 Celgene Corporation 47 Constellation Pharmaceuticals, Inc. 48 Daiichi Sankyo Company, Limited 49 Deciphera Pharmaceuticals, LLC 50 Eisai Co., Ltd. 51 EpiZyme, Inc. 52 Galena Biopharma, Inc. 53 Gamida Cell Ltd. 54 HEC Pharm Co., Ltd. 55 Hybrigenics S.A. 56 Ilyang Pharmaceutical Co., Ltd 57 Incyte Corporation 58 Jiangsu Hansoh Pharmaceutical Co., Ltd. 59 Juno Therapeutics Inc. 60 JW Pharmaceutical Corporation 61 KaloBios Pharmaceuticals, Inc. 62 Karyopharm Therapeutics, Inc. 63 Lixte Biotechnology Holdings, Inc. 64 Millennium Pharmaceuticals, Inc. 65 Mirna Therapeutics, Inc. 66 Natco Pharma Limited 67 Novartis AG 68 Onconova Therapeutics, Inc. 69 Ono Pharmaceutical Co., Ltd. 70 Oribase Pharma 71 Pfizer Inc. 72 Pharma Mar, S.A. 73 PharmaEssentia Corporation 74 Selvita SA 75 Shenogen Pharma Group Ltd. 76 Stemline Therapeutics, Inc. 77 Sun Pharma Advanced Research Company Ltd. 78 Targazyme, Inc. 79 Teva Pharmaceutical Industries Limited 80 Threshold Pharmaceuticals, Inc. 81 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 82 Assessment by Monotherapy Products 82 Assessment by Combination Products 83 Assessment by Target 84 Assessment by Mechanism of Action 89 Assessment by Route of Administration 93 Assessment by Molecule Type 95 Drug Profiles 97 (camptothecin + podofilox) - Drug Profile 97 ABL-001 - Drug Profile 98 AIC-47 - Drug Profile 99 ALT-803 - Drug Profile 100 anagrelide hydrochloride CR - Drug Profile 103 APR-246 - Drug Profile 104 ARGX-110 - Drug Profile 106 azacitidine - Drug Profile 109 binimetinib - Drug Profile 113 BL-8040 - Drug Profile 118 BMS-833923 - Drug Profile 120 bosutinib - Drug Profile 122 BP-100101 - Drug Profile 125 BPX-501 - Drug Profile 127 BST-236 - Drug Profile 129 CAN-04 - Drug Profile 130 Cell Therapy to Target GM-CSF for Oncology - Drug Profile 132 Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 134 CPI-0610 - Drug Profile 135 CT-413 - Drug Profile 136 CWP-291 - Drug Profile 137 D-12PGJ3 - Drug Profile 139 D-824 - Drug Profile 140 danusertib - Drug Profile 141 Dendritic Cell Therapy for Chronic Myeloid Leukemia - Drug Profile 143 Dendritic Cell Therapy for Hematological Malignancies - Drug Profile 144 Dendritic Cell Therapy for Oncology - Drug Profile 145 Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile 146 Dendritic Cell Therapy to Target WT1 for Oncology - Drug Profile 147 DS-3032 - Drug Profile 148 E-6201 - Drug Profile 149 erismodegib - Drug Profile 151 ETC-027 - Drug Profile 154 ETC-219 - Drug Profile 155 evofosfamide - Drug Profile 156 flumatinib mesylate - Drug Profile 164 Gene Therapy for Oncology - Drug Profile 165 guadecitabine - Drug Profile 166 Hu8F4 - Drug Profile 170 inecalcitol - Drug Profile 171 inotuzumab ozogamicin - Drug Profile 174 interferon alfa-2a - Drug Profile 176 interferon alfa-2b - Drug Profile 177 ipilimumab - Drug Profile 178 ixazomib citrate - Drug Profile 183 JTCR-016 - Drug Profile 187 KB-004 - Drug Profile 188 LB-100 - Drug Profile 190 LB-102 - Drug Profile 192 lirilumab - Drug Profile 194 lurbinectedin - Drug Profile 196 MJ-05 - Drug Profile 199 MRX-102 - Drug Profile 200 MRX-34 - Drug Profile 202 napabucasin - Drug Profile 204 NiCord - Drug Profile 207 nivolumab - Drug Profile 208 NOV-120501 - Drug Profile 216 NRCAN-019 - Drug Profile 217 omacetaxine mepesuccinate - Drug Profile 219 ORB-0001 - Drug Profile 222 pegaspargase - Drug Profile 223 PF-114 - Drug Profile 225 pinometostat - Drug Profile 226 ponatinib hydrochloride - Drug Profile 229 PRI-724 - Drug Profile 232 radotinib - Drug Profile 234 rebastinib tosylate - Drug Profile 236 rigosertib sodium - Drug Profile 238 ropeginterferon alfa-2b - Drug Profile 243 ruxolitinib phosphate - Drug Profile 246 SEL-24B489 - Drug Profile 251 selinexor - Drug Profile 252 SL-401 - Drug Profile 258 SL-501 - Drug Profile 260 Small Molecule to Inhibit ADAR1 for Chronic Myeloid Leukemia - Drug Profile 261 Small Molecules to Inhibit Abl Tyrosine Kinase for CML - Drug Profile 262 Small Molecules to Inhibit BCR-ABL for CML - Drug Profile 263 Small Molecules to Inhibit Bcr-Abl for CML and Pancreatic Cancer - Drug Profile 264 Small Molecules to Inhibit BRCA2/Rad51 Interaction for Cancer - Drug Profile 265 SNG-1153 - Drug Profile 266 SNG-162 - Drug Profile 267 SUNK-706 - Drug Profile 269 TR-120 - Drug Profile 270 trametinib dimethyl sulfoxide - Drug Profile 271 TZ-101 - Drug Profile 274 Vaccine to Target Bcr-Abl Tyrosine Kinase for Chronic Myeloid Leukemia - Drug Profile 276 Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile 277 Vaccine to Target WT1 for CML and AML - Drug Profile 278 Vaccine to Target WT1 for Oncology - Drug Profile 279 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Recent Pipeline Updates 280 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 414 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 420 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 422 Featured News & Press Releases 422 Appendix 433 Methodology 433 Coverage 433 Secondary Research 433 Primary Research 433 Expert Panel Validation 433 Contact Us 433 Disclaimer 434
List of Tables
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2015 18 Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H2 2015 19 Number of Products under Development by Companies, H2 2015 21 Number of Products under Development by Companies, H2 2015 (Contd..1) 22 Number of Products under Development by Companies, H2 2015 (Contd..2) 23 Number of Products under Development by Companies, H2 2015 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H2 2015 26 Comparative Analysis by Late Stage Development, H2 2015 27 Comparative Analysis by Clinical Stage Development, H2 2015 28 Comparative Analysis by Early Stage Development, H2 2015 29 Comparative Analysis by Unknown Stage Development, H2 2015 30 Products under Development by Companies, H2 2015 31 Products under Development by Companies, H2 2015 (Contd..1) 32 Products under Development by Companies, H2 2015 (Contd..2) 33 Products under Development by Companies, H2 2015 (Contd..3) 34 Products under Development by Companies, H2 2015 (Contd..4) 35 Products under Investigation by Universities/Institutes, H2 2015 36 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 37 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor BioScience Corporation, H2 2015 38 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Aprea AB, H2 2015 39 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by arGEN-X BV, H2 2015 40 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015 41 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Array BioPharma Inc., H2 2015 42 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 43 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Baxalta Incorporated, H2 2015 44 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015 45 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings, Inc., H2 2015 46 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Biogenomics Limited, H2 2015 47 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx, Ltd., H2 2015 48 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioSight Ltd., H2 2015 49 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical, Inc., H2 2015 50 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2015 51 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H2 2015 52 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corporation, H2 2015 53 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015 54 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 55 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015 56 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eisai Co., Ltd., H2 2015 57 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by EpiZyme, Inc., H2 2015 58 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galena Biopharma, Inc., H2 2015 59 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd., H2 2015 60 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by HEC Pharm Co., Ltd., H2 2015 61 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics S.A., H2 2015 62 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co., Ltd, H2 2015 63 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corporation, H2 2015 64 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015 65 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Juno Therapeutics Inc., H2 2015 66 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corporation, H2 2015 67 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015 68 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 69 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015 70 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 71 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Mirna Therapeutics, Inc., H2 2015 72 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Limited, H2 2015 73 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H2 2015 74 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Onconova Therapeutics, Inc., H2 2015 75 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 76 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Oribase Pharma, H2 2015 77 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc., H2 2015 78 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pharma Mar, S.A., H2 2015 79 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corporation, H2 2015 80 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Selvita SA, H2 2015 81 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shenogen Pharma Group Ltd., H2 2015 82 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics, Inc., H2 2015 83 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 84 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Targazyme, Inc., H2 2015 85 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 86 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 87 Assessment by Monotherapy Products, H2 2015 88 Assessment by Combination Products, H2 2015 89 Number of Products by Stage and Target, H2 2015 91 Number of Products by Stage and Mechanism of Action, H2 2015 96 Number of Products by Stage and Route of Administration, H2 2015 100 Number of Products by Stage and Molecule Type, H2 2015 102 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Recent Pipeline Updates, H2 2015 286 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H2 2015 420 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..1), H2 2015 421 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..2), H2 2015 422 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..3), H2 2015 423 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..4), H2 2015 424 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..5), H2 2015 425 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H2 2015 426 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products (Contd..1), H2 2015 427
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
